A Phase II Study of Sorafenib in Combination with Cisplatin and 5-fluorouracil in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Yuanlu (April) Sun; Cong Xue; Qitao Yu; Jian-Ji Pan; Li Zhang

doi:10.1200/jco.2012.30.15_suppl.5538

A Phase II Study of Sorafenib in Combination with Cisplatin and 5-fluorouracil in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Yuanlu (April) Sun
, Cong Xue
, Qitao Yu
, Jian-Ji Pan
, Li Zhang

University of Missouri-St. Louis

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	30
DOIs	https://doi.org/10.1200/jco.2012.30.15_suppl.5538
State	Published - 2012

Disciplines

Nursing

Access to Document

10.1200/jco.2012.30.15_suppl.5538License: Unspecified

Cite this

@article{1b67dd48f4794a158ab696633de7dfa2,

title = "A Phase II Study of Sorafenib in Combination with Cisplatin and 5-fluorouracil in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma",

author = "Sun, \{Yuanlu (April)\} and Cong Xue and Qitao Yu and Jian-Ji Pan and Li Zhang",

note = "Background: Nasopharyngeal carcinoma (NPC) is a disease with distinctive epidemiology and clinical behavior compared with Head and neck cancer (HNC) and more common in South-East Asia. Sorafenib monotherapy has been shown modest anticancer activity in HNC and NPC ( C Elser et al; JCO 2007).",

year = "2012",

doi = "10.1200/jco.2012.30.15\_suppl.5538",

language = "American English",

volume = "30",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - A Phase II Study of Sorafenib in Combination with Cisplatin and 5-fluorouracil in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

AU - Sun, Yuanlu (April)

AU - Xue, Cong

AU - Yu, Qitao

AU - Pan, Jian-Ji

AU - Zhang, Li

N1 - Background: Nasopharyngeal carcinoma (NPC) is a disease with distinctive epidemiology and clinical behavior compared with Head and neck cancer (HNC) and more common in South-East Asia. Sorafenib monotherapy has been shown modest anticancer activity in HNC and NPC ( C Elser et al; JCO 2007).

PY - 2012

Y1 - 2012

UR - https://ascopubs.org/doi/abs/10.1200/jco.2012.30.15_suppl.5538

U2 - 10.1200/jco.2012.30.15_suppl.5538

DO - 10.1200/jco.2012.30.15_suppl.5538

M3 - Article

VL - 30

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

A Phase II Study of Sorafenib in Combination with Cisplatin and 5-fluorouracil in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Disciplines

Access to Document

Other files and links

Cite this